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Abstract: Introduction: Variations in the apoprotein apoA-I and apoB genes have been associated with their serum 
concentration, and thus with Coronary Artery Disease (CAD). This study determined the relationship between 
polymorphism and the serum concentration of apoA-I and apoB in a group of patients with angiographically documented 
CAD. 
Materials and methods: Polymorphic sites, XbaI (in apoB), and MspI (in apo A-I) and serum concentrations in these 
lipoproteins were determined in a population of 231patients classified into two groups: patients with significant CAD 
(coronary obstruction 50%) and patients with mild CAD (coronary obstruction <50%); the apoB/apoA-I ratio was then 
calculated. 
Results: It was found that the M2 allele in the apoA-I acts as a risk factor for coronary artery disease, odds 
ratio=1.78(confidence interval: 1.21 – 2.61), p =0.002. Nosignificant differences were found between the apoA-I 
concentration values and the corresponding MspI polymorphism genotypes in the two study groups. Meanwhile, the 
apoB concentration presented significant differences among the XbaI (p=0.027) polymorphism genotypes, with greater 
values for the heterozygous genotype in patients with CAD50%. Likewise, a significantly abnormal difference was 
evident in the apoB/apoA-I ratio among the two groups, with a greater value for patients with mild CAD.  
Conclusion: the data showed that the M2allele may be a risk factor for CAD in this population. Additionally, it showed 
that there is a relationship between apoB serum concentration and XbaI polymorphism; relationship which manifests 
itself more strongly in patients with CAD. There was no relationship established between the MspI polymorphism of 
apoA-I and its serum concentration. Other studies are necessary in order to establish the anomalous behavior of the 
apoB/apoA-I relation in this population. 
Keywords: Apolipoprotein, Polymorphism, Coronary artery disease (CAD), ApoB/apoA-I ratio. 
INTRODUCTION 
Cardiovascular Diseases (CVDs) are the main 
cause of morbidity and mortality worldwide. Reducing 
cholesterol levels, controlling blood pressure, and 
renouncing cigarett cves are control strategies used to 
prevent cardiovascular diseases. However, there is an 
important causative genetic factor [1, 2]. Candidate 
genes related to lipoprotein metabolism and their 
related apoproteins are found, among others, to be 
associated with CDVs [3].   
Recent studies have suggested that apolipoprotein 
B (apoB) and apolipoprotein A-I (apoA-I) may be non-
traditional markers of cardiovascular risk [4, 5]. ApoA-I 
activates the enzymes that takes part in transport the 
cholesterol from tissues to a high-density lipoprotein 
(HDL). It also allows the HDL to be recognized by the 
liver receptors, thus joining them by the end of the  
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transport. The apoA-I concentration can be measured 
directly and it tends to reflect the HDL concentration. 
This fact has led some experts to believe that apoA-I 
could be a better indicator of atherogenic risk than HDL 
[5]. 
ApoA-I deficit appears to correlate with an 
increased risk of developing CAD and peripheral 
vascular disease [6]. Generally an increase of apoA-I 
does not represent a problem, but a decrease is 
associated with low levels of HDL and reduced 
elimination of cholesterol in the body [7]. Low levels of 
apoA-I along with high levels of apoB are associated 
with an increased risk of coronary artery disease [8]. 
Some genetic alterations lead to apoA-I deficiency, 
and consequently to low concentrations of HDL [9, 10]. 
Individuals with these conditions tend to have 
hyperlipidemia and higher concentrations of low density 
lipoprotein (LDL). They often suffer from advanced 
atherosclerosis (formation of fatty plaques and 
hardened tissue in the arteries) that can lead to 
coronary and cerebral events [6]. 
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Likewise, apoB tends to indicate LDL 
concentrations and can be measured directly. Many 
experts believe that the concentration of apoB-100 may 
be a better risk indicator of atherosclerotic heart 
disease than LDL [4, 5, 8]. Others disagree, but claim 
that apoB and other cardiac risk markers, such as 
apoA-I, Lp(a), and C-reactive protein (CRP), can 
provide valuable additional information. 
In recent studies have expressed apoB and apoA-I 
in terms of apoB/apoA-I ratio and seems to be effective 
in cardiovascular disease risk characterization [4, 5]. 
The present study aims to determine the 
relationship between polymorphism and the serum 
concentrations of the apoA-I and apoB in a group of 
patients with mild versus significant coronary artery 
disease. 
MATERIALS AND METHODS  
Population and Sample  
The study included 231 patients of both genders (92 
females/139 males), who were sequentially admitted to 
the Quindío Hemodynamics Center in Armenia-
Colombia between the years 2008-2009. These 
patients had a clinical necessity for a coronary 
angiography, a history of cardiac ischemia, and 
suffered at least one major cardiovascular event. The 
study did not include pregnant patients, or patients with 
dysbetalipoproteinemia, diabetes, hyperlipidemia, 
uncontrolled hypertension, kidney damage, or 
untreated idiopathic nephrotic syndrome, because 
these states or diseases alter plasma lipids. Only the 
patients’ basic data (lipid profile and grade of coronary 
obstruction) was accessible. All patients were 
prospectively included and signed an informed consent 
prior to the angiography. They also filled out a 
questionnaire used to obtain basic demographic data 
(age, gender, diet, personal and family medical history, 
and other cardiovascular risk factors). The study was 
approved by the Bioethics Committee at Universidad 
del Quindío. 
Coronary Angiography 
The coronary angiography was conducted 
according to standard methods by an intervening 
physician. For the evaluation of the lesions, the 
coronary quantitative analysis (CQA) method was used 
by two independent observers unaware of the 
laboratory results. Results showed inter-observer 
variability was at 3.8%. Obstructive disease of the 
coronary arteries was defined as one or more stenos is 
50% in at least one major coronary artery or in any of 
its main ramifications. This procedure permitted the 
classification of patients into two groups: the first group 
had a coronary obstruction greater to or equal to 50% 
(CAD  50%), and the second group had a coronary 
obstruction between zero and less than 50% (CAD < 
50%).  
Blood Samples and Biochemical Analyses  
After 8-12 hours of fasting, the samples were 
obtained during the angiographic procedure and sent to 
the laboratory. The laboratory personnel did not know 
the patient information and could only identify the 
samples by number. For lipid profile analysis, blood 
collected in dry tubes was used. Serum was obtained 
through centrifugation at 2500 g for 15 minutes at 4 °C, 
separated in micro-tubes, and stored at -20 °C until 
use.  
The quantification of apoA-I and apoB was 
performed in serum using the Biosystems commercial 
kit and following the manufacturer's instructions. 
Likewise, the apoB/apoA-I ratio was assessed as a risk 
factor for cardiovascular disease. 
Molecular Analysis: XbaI and MspI Polymorphism 
ApoB and ApoA-I genes have polymorphic sites, 
including those due to the presence/absence of the 
cutting site of the restriction enzymes (restriction 
fragment length polymorphism; RFLP), such as XbaI 
and MspI. RFLP produces two alleles and three 
genotypes in each gene, called M1 and M2 for MspI 
and X1 and X2 for Xbal. For this purpose DNA 
extraction was carried out using the Wizard Genomic 
DNA Purification Kit (Promega) in total blood and 
following the manufacturer's instructions. 
ApoB Gene Amplification by PCR  
The XbaI polymorphism of apoB was determined by 
allele specific amplification using the polymerase chain 
reaction (PCR). PCR was performed using the 
following procedure: 500 ng of genomic DNA was 
added to PCR 1X buffer, MgCl2 (1.5 mM), primers (0.4 
M), dNTPs (200μM), dimethyl sulfoxide (DMSO) 
(10%), and Taq polymerase (3U) for a total volume of 
50l. The PCR was performed with 35 successive 
cycles with the following times and denaturation 
temperatures at 95°C for 1min, hybridization at 60°C 
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for 50sec, and an extension at 70°C for 2 min. Then, 
25μl of the amplified product (144pb) underwent a 
digestion by applying 10UI of the XbaI restriction 
enzyme at 37°C during 3 hours. The resulting 
restriction fragments were separated by 
electrophoresis in a 1.5 % agarose and visualized on a 
UV transilluminator after staining the gel with ethidium 
bromide 
ApoA-I Gene Amplification by PCR  
The polymorphism of the apoA-I gene was 
determined by PCR. PCR was performed using the 
following procedure: 150 ng of genomic DNA 
containing PCR 1X buffer, Cl2Mg (1.5mM), primers 
(20pmol), dNTPs (20mmol), and Taq polymerase 
(2.5U) for a total volume of 50l. The PCR was 
performed with 35 successive cycles with the following 
times and denaturation temperatures at 90°C during 
30sec, hybridization at 60°C for 30sec, and an 
extension at 72°C for 1 min. The amplified product was 
incubated for 3 hours with the MspI enzyme. The 
resulting restriction fragments were separated by 
agarose electrophoresis at 1.5 % and visualized on a 
UV transilluminator after dyeing the gel with ethidium 
bromide. 
Statistical Analysis 
The estimate of allelic differences was found by 
Allele-count method. The chi-square test was used to 
evaluate whether the allelic frequencies observed were 
consistent with those expected in accordance with the 
“Hardy-Weinberg law”. These data were organized 
according to descriptive statistics such as mean and 
confidence intervals at 95% of the variables identified 
in the study, initially as a whole. The concentrations of 
apolipoproteins in each group, according to the 
genotypes of apoA-I and apoB were compared using 
the Kruskal-Wallis test. The differences according to 
gender or obstruction were determined by the Mann-
Whitney test, considering there is statistically 
significance when p <0.05.  
RESULTS  
General Characteristics of the Study Population 
The 231 patients in the study were classified into 
two groups according to the degree of coronary arterial 
disease: 1) patients with CAD  50% (114 (49.35%)), 
considered patients with significant obstruction and, 2) 
patients with CAD <50% (117 (50.61%)), considered 
patients without significant obstruction (mild CAD). Of 
the total population, 92 patients were women and 139 
were men. Out of the patients with CAD <50%, 58 were 
women and 59 were men; whereas in the group of 
patients with CAD  50%, 34 were women and 80 were 
men.  
The general data of the population and the groups 
is presented in Table 1. 
Age was significantly different between the two 
study groups; the oldest were the patients in the group 
with (more severe) CAD. Differences were also evident 
with respect to gender, where for every woman with 
coronary artery disease there were 2.3 men with the 
disease (OR = 2.3; 95% CI 1.34 – 3.97). No significant 
differences were found in the apoA-I and apoB serum 
concentrations. 
Apolipoprotein A1 and B Polymorphism 
The genotype and allele frequencies are presented 
in Table 2. The polymorphisms analyzed are not 
distributed according to the Hardy Weinberg law and 
Table 1: Baseline Characteristics of the Two Groups 
Variable 
Total 
n = 231 
CAD < 50% 
n = 117 
CAD > 50% 
n = 114 
P Value 
Age (years) 61.6 ± 11.5 59.6 ± 12.5 63.6 ± 9.8 0.021* 
Sex Distribution (Female/Male) 92/139 58/59 34/80 0.002* 
Apolipoprotein A-1  
(mg/dl) 
74.1 ± 29.5 72.0 ± 31.6 76.2 ± 27.2 NS 
Apolipoprotein B  
(mg/dl) 
135 ± 62.7 139.5 ± 66.4 130.4 ± 58.7 NS 
apoB/apoA-1 2.23 ± 1.5 2.38 ± 1.4 2.07 ± 1.6 0.013* 
*p0.05; significant; NS Not significant.  
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showed X
2
 values of 78.8 and 64.9 for apoA-I 
polymorphism and XbaI polymorphism, respectively. 
The study showed that the M2 allele behaves as a 
risk factor for coronary artery disease, since an odds 
ratio of OR = 1.78 (CI: 1.21–2.61) was obtained with a 
value of p=0.002 when comparing the allele 
frequencies of this polymorphism among the patients 
with CAD 50 and the patients with mild CAD. There 
were no patients with the genotype X1/X1 of the XbaI 
polymorphism of the apoB. The most common alleles 
were the X2 allele for the XbaI polymorphism and the 
M1 allele for the apoA-I polymorphism 
Polymorphism and Levels of ApoA-I and ApoB 
In the total population, the results of the relationship 
between the MspI genotypes of apoA-I and its serum 
concentration presented higher levels in the 
heterozygous genotype M1/M2 with an average of 
77.4mg/dl. The lowest results, 72.8mg/dl, were found in 
the genotype M2/M2. However, there were no 
statistically significant differences between the 
concentration and the genotypes of this polymorphism 
(Figure 1). 
In contrast, the serum concentrations of apoB 
showed statistically significant relationships with the 
Table 2:  Frequencies of apoA-I and apoB Alleles and Genotypes in of the Two Groups 
Polymorphisms Total (%) CAD< 50% CAD> 50% P Value  
XbaI genotype 
X1/X1 
X1/X2 
X2/X2 
XbaI allele 
X1 
X2 
n = 231 
- 
160 (69.3) 
71 (30.7) 
80 (34.6) 
151 (65.4) 
n = 117 
- 
78 (66.7) 
39 (33.3) 
39 (33.3) 
78 (66.7) 
n = 114 
- 
82 (71.9) 
32 (28.1) 
41 (36) 
73 (64) 
 
NS 
NS 
 
MspI genotype  n = 231 n = 117 n = 114   
M1/M1 
M1/M2 
M2/M2 
MspI allele 
M1 
M2 
127 (55) 
44 (19) 
60 (26) 
149(64.5) 
82 (35.5) 
73 (62.4) 
20 (17.1) 
24 (20.5) 
83 (70.9) 
 34 (29.1) 
54 (47.4) 
24 (21.1) 
36 (31.6) 
66 (57.9) 
48 (42.1) 
NS 
*0.002 
 
*p0.05; significant; NS Not significant. 
 
Figure 1: Polymorphism and Levels of ApoA-I.  
In the all patients and patients with CAD the MspI genotypes of apoA-Iand its serum concentration presented higher levels in 
the heterozygous genotype M1/M2. However, there were no statistically significant differences. CAD = Coronary arterial 
disease. M1 and M2 alleles from MspI polymorphism in apo A-I. 
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XbaI polymorphism genotypes, wherein the 
concentration of the heterozygous genotype X1/X2 was 
141.2mg/dl, and 121.0 mg/dl p=0.027 for the genotype 
X2/X2 (Figure 2). 
In the group of patients with mild CAD, no 
significant differences were found between the values 
of apoA-I concentration and the corresponding MspI 
polymorphism genotypes. However, it should be noted 
that the genotype M1/M1 had the greatest 
concentrations with a value of 74.5mg/dl, followed by 
the genotype M1/M2 and the genotype M2/M2 with 
69.6mg/dl and 66.5mg/dl, respectively (Figure 1). 
Similarly, no statistical relationships were found 
between the XbaI polymorphism and apoB 
concentrations, being greater the values of 
concentration in the genotype X1/X2 than in the 
homozygous for X2 with 143.5mg/dl and 131.6mg/dl, 
respectively (Figure 2). 
By observing this group of patients according to 
gender, it was determined that there were no 
differences between the concentrations of both 
apolipoproteins and gender; in which the values of 
women in relation to apoA-I are greater than in men, 
whereas the opposite occurs with apoB. Reasonably, 
the apoB/apoA-I ratio presents the same tendency 
without statistical differences. 
There were no significant differences between the 
values of concentration of apoA-I with its polymorphism 
in patients with CAD (Figure 1). Contrary to what was 
discovered in the apoB, where its concentration varied 
with the polymorphism with significant differences 
(p=0.009). The heterozygous genotype had a greater 
concentration, 139.1mg/dl (CI 125.7 – 152.4), while 
that of the homozygous genotype for X2 was 
108.1mg/dl (91.1 – 125.1) (Figure 2). Finally, the 
concentration of apoA-I and apoB was not statistically 
different between men and women. 
Analysis of Genotypes and Alleles by Gender 
Of the 92 women studied, 34 had significant CAD 
and 58 had mild CAD. Neither of the two groups 
showed differences among the concentrations of both, 
apolipoproteins and their respective polymorphisms. By 
contrast, in the men studied a statistically significant 
relationship between XbaI genotypes and the 
concentration of apoB (p=0.014) was observed. Table 
(3 and 4). 
DISCUSSION 
In recent decades, studies focused on determining 
the factors that impact the development of 
cardiovascular disease have concentrated on linking 
biochemical and genetic aspects. There have analyzed 
the relationship between molecules that favor the 
appearance of the disease or that function as protector 
elements, with genetic variations in their genes and the 
importance that these relationships can have in the 
clinic, with respect to timely diagnosis and appropriate 
treatment [1, 2].  
It is well documented that plasma lipoprotein 
concentrations, especially the increase in total 
 
Figure 2: Polymorphism and Levels of ApoB.  
In the all patients and patients with CAD and mild CAD, the XbaI genotypes of apoB and its serum concentration presented 
higher levels in the heterozygous genotype X1/X2. However in total population and patients with CAD there were statistically 
significant differences. CAD = Coronary arterial disease. X1 and X2 alleles from MspI polymorphism in apoB. 
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cholesterol (TC), low density lipoprotein (LDL), very low 
density lipoproteins (VLDL), and the decrease of high-
density lipoprotein (HDL), behave as risk factors for the 
development of coronary artery diseases [11]. 
Moreover, it has been suggested that there is a 
protective effect of HDL and the majority of its 
apolipoprotein (apoA-I) against the onset of the 
disease. This effect may be mediated primarily by the 
activation or stimulation of cholesterol efflux from 
peripheral cells; even more so, if it is taking into 
account the anti-inflammatory and antioxidant 
properties of the apo contributing to its anti-atherogenic 
effects [12].  
It is important to remember that genetic variations in 
the apoB gene, such as XbaI polymorphism, may affect 
its plasma concentration as well as the concentration or 
functions of lipoproteins that contain it (LDL and VLDL) 
[13]. This is due to the alteration in the rate of 
secretion, structural stability, receptor affinity, or 
interaction with other lipoproteins or enzymes (for 
example, lipoprotein lipase), disrupting the metabolism 
of these lipoproteins [14-17]. 
In this study the data showed that the concentration 
of apoB in plasma is greater in patients with mild CAD 
than in patients with CAD. The greatest values for both 
groups were found in the heterozygous genotypes 
X1/X2, finding a significant difference in the group of 
patients with CAD. This result is consistent with a 
report based on a Chinese population [14], in which the 
greatest apoB concentration values were found for X1 
alleles, in both subjects and controls. Conversely, 
Hubacek et al. in 1998 [15], Rantala et al. in 2000 [16], 
and Scartezini et al. in 2003[17], reported that the 
concentration of apoB were significantly increased in 
homozygous genotype X2/X2. The results present a 
relationship between polymorphism and the 
concentration of apoB in plasma, which generated an 
important question; if polymorphism is a synonymous 
mutation of character where the amino acid sequence 
is not affected, what is the reason for, or how does the 
mutation affect the expression or the metabolism of the 
protein? A possible answer to this question could be 
that the change of this base (CT) decreases the 
affinity of potential ribonucleases that inhibit the 
transcription of this gene or other circumstances [18]. 
On the other hand, the distribution of XbaI 
polymorphism for the mutated allele X2 was lower 
(64%) in patients with CAD than in patients with mild 
CAD (66.7%) and no significant differences were 
Table 3:  Apolipoproteins Concentration by Gender in of the Two Groups  
Women Men 
Variables Total CAD Mild CAD P Total CAD Mild CAD  P 
n 92 34 58   139 80 59   
Apo A-1 (mg/dL) 74.9 ± 31.4 77.7 ± 28.6 73.2 ± 32.1 0.62 73.6 ± 28.3 75.6 ± 26.7 70.81 ± 30.2 0.542 
Apo B (mg/dL) 136.8 ± 70.1 139.2 ± 65.4 135.4 ± 73.2 0.62 133.8 ± 57.6 126.6 ± 55.7 143.57 ± 59.2 0.139 
Ratio  
ApoB/ApoA-1 2.3 ± 1.6 2.28 ± 2.1 2.3 ± 1.4 0.43 2.2 ± 1.4 1.98 ± 1.4 2.47 ± 1.4 0.010 
CAD = Coronary arterial disease. 
 
Table 4: Apolipoproteins Concentration by Gender and Polymorphism in of the Two Groups  
  Apolipoprotein B (mg/dL) Apolipoprotein A -1 (mg/dL) 
  Polymorphism XbaI   Polymorphism MspI   
GENDER X1/X1 X1/X2 X2/X2 p M1/M1 M2/M2 M2/M2 p 
Women 
 (CI 95%)  0 139.0 ± 70.3 131.1 ± 70.6 0.579 76.0 ± 32,7 81.3 ± 30,5 69.3 ± 30 0.334 
Men 
(CI 95%) 0 142.7 ± 60.2 115.1 ± 47 0.014 72.0 ± 28 75.2 ± 28.5 75.9 ± 29.3 0.827 
CAD = Coronary arterial disease. 
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found.  Meanwhile, studies of a Brazilian populations 
reported a greater frequency of both, the allele X2 and 
its homozygote genotype X2/X2, in patients with 
coronary artery disease compared to that of the control 
patients [16, 17].  In our study population there was no 
genotype X1/X1 present, similarly to that discovered by 
Ju-Pin Pan et al. in 1995 [14], who studied a population 
of 301 Chinese individuals of both genders and found 
that there were more individuals exhibiting the allele X2 
in the group of patients with mild CAD than in the group 
of patients with CAD. However, the results of genotypic 
and allelic distribution for the XbaI polymorphism 
contrast with those reported in Caucasian populations, 
in which the proportions of such alleles are very similar 
in both, controls and patients [19], similar to our study. 
It has been established that the presence of high 
concentrations of HDL in plasma is a protective factor 
against CAD. However, it is important to emphasize 
that it is the quality and function of HDL that has a 
great beneficial impact on the health of patients. This 
lipoprotein presents apoA-I as the main protein 
component, thus playing an important role in its 
metabolism, since apoA-I is the primary inducer of the 
lecithin-cholesterol acyltransferase (LCAT) enzyme 
activity and it is the main component in the reverse 
transport of cholesterol [20]. In this sense its genetic 
variation influences its concentration and 
atheroprotective function. 
In relation to this, in the present study, the MspI 
polymorphism of the apoA-I gene had a higher allele 
frequency for the mutant allele M2 in patients with CAD 
(42.1%) compared to the frequency found in patients 
without significant disease (29.1%). It was also 
determined that this allele acts as a risk factor for 
coronary obstruction in our population, with a value of 
OR = 1.78. These results are contrary to that reported 
by Dixit et al. in 2007[21], who observed that both allele 
frequencies and genotype have similar distribution in 
patients and controls, and also that the homozygous 
genotype M2/M2 was uncommon. 
The concentration of apoA-I is similar to the three 
polymorphism genotypes of apoA-I, in patients with 
CAD as well as in patients with mild CAD. Similar 
results were reported by Pulkkinen et al. in a population 
of western Finland in 2000 [22], where the values of 
concentration of apoA-I showed no significant 
difference among the genotypes or among patients and 
controls. Nonetheless, the results of the study being 
presented showed a high frequency of the M2 allele 
(35.5%) as well as of the genotype M2/M2 (26%) in 
comparison to other studies [22,23], which report that 
this allele has a low frequency (4.1%). It has been 
suggested that this mutation may generate 
hypomethylation of the gene, which would cause an 
increase of its expression; whereas if there is no 
variation some issues/drawbacks may arise at the time 
of initiation of the transduction of mRNA [24, 25]. 
The apparent contradictions that can arise from 
different studies in relation to allele frequencies, 
genotypic of genotype concentration ratio for the XbaI 
and apoA-I polymorphism, may be associated to the 
variation and genetic recombination that occurs during 
the crossings of different races. In fact, the variations 
manifested within the same group can be possible 
caused by pressures of expression related to the 
influence of environmental factors.  
Another situation of analysis within our results is the 
ratio of the concentration of apolipoproteins studied in 
relation to the disease. It has been documented that 
apoA-I in HDL is a protective factor, therefore a greater 
concentration was expected in patients with mild CAD; 
similarly, a lower concentration of apoB was expected, 
as described in other studies [19, 22]. Nonetheless, it 
should be noted that the concentration-disease ratio 
implies mechanisms more complicated than a simple in 
vitro measurement. 
This study also found abnormal results for the 
apoB/apoA-I ratio of the concentrations of the two 
apoproteins, and therefore it cannot be used as a 
predictor of risk of CAD as described by some authors 
[26, 27]. For the population of the present study, the 
findings in the concentration of lipoproteins and 
apoB/apoA-I ratio suggest that the concentration of 
LDL and HDL as such do not have a great impact on 
the development of coronary artery disease in these 
patients, and that they are the factors involved in the 
stated pathology. This has been demonstrated through 
various studies of the group, in which it is 
demonstrated that patients with and with mild coronary 
artery disease have normal LDL and HDL at the lower 
limit of the reference point [28].  
In conclusion, this study found that there is a 
relationship between the concentration of apoB and the 
XbaI polymorphism genotypes of this apolipoprotein. 
This relationship manifests itself most strongly in 
patients with CAD, whereas no relationship was 
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established between the MspI polymorphism of apoA-I 
and its serum concentration. It was also found that the 
M2 allele may be a risk factor for coronary artery 
disease in our population 
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